Considering previous studies and our univariate and multivariate analyses in different stratifications of 975 HER2-negative breast cancer patients, we conclude that for HER2-negative cases undergoing NAC in the Chinese population, stratifying based on HR, particularly ER, can tailor more personalized treatment strategies for patients with varying HER2 statuses. This evidence concerns the gene ERBB2 and breast carcinoma.